Retatrutide
Retatrutide is a next-generation triple agonist of the GLP-1, GIP, and glucagon receptors developed for weight loss; research protocols typically start at 1 mg subcutaneously once weekly, titrating up to a 12 mg ceiling only if weight loss stalls.
Adults with significant metabolic or weight-management goals; research-context use under physician supervision is strongly indicated due to potent multi-receptor activity
Retatrutide is a next-generation triple-receptor agonist developed by Eli Lilly, simultaneously activating GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This three-way pharmacology distinguishes it from earlier obesity therapeutics: GLP-1 monotherapy (semaglutide / Ozempic / Wegovy) drives 12-15% mean weight loss in trials, GLP-1+GIP combinations (tirzepatide / Mounjaro / Zepbound) drive 20-22%, and Retatrutide's Phase 2 trials demonstrated 24% mean weight loss at 48 weeks. That's the largest weight-loss magnitude reported for any pharmaceutical agent to date.
The glucagon-receptor agonism is the novel addition: it increases energy expenditure and lipolysis (fat breakdown), complementing the appetite-suppression effects of GLP-1/GIP. Side-effect profile mirrors the GLP-1 class (nausea, gastrointestinal disruption particularly during dose escalation, occasional injection-site reactions) with the addition of mild liver-enzyme elevations attributed to glucagon signaling. Retatrutide is currently in Phase 3 trials (TRIUMPH-1, TRIUMPH-2, TRIUMPH-OUTCOMES) targeting obesity, type 2 diabetes, and cardiovascular-outcome endpoints.
Not yet FDA-approved as of this writing; expected approval timeline 2026-2027. Used in research contexts under physician supervision, particularly for severe obesity or metabolic syndrome unresponsive to first-line GLP-1 therapy.
Subcutaneous injection once weekly. Dose-escalation protocols are typical in research, starting at 2mg and titrating upward over 8-12 weeks based on tolerance
Initial appetite-suppression and weight changes typically within 2-4 weeks; full metabolic effects develop over 24-48 weeks of consistent use
Generally used standalone given the breadth of its receptor activity
Log every dose, count every vial, and verify your batches — free in the goodtides app.
This page is educational reference material about compounds studied in research settings. It is not medical advice, and nothing here is a recommendation to buy, possess, or use any compound. Research findings described are from published literature; individual compounds may not be approved for human use. Talk to a licensed clinician about anything that affects your health.